Over 350 Total Lots Up For Auction at Two Locations - NY 03/21, FL 03/22

Volpara signs distribution agreement to sell Transpara, Screenpoint Medical's AI solution for breast cancer detection

Press releases may be edited for formatting or style | July 23, 2019 Health IT Women's Health
WELLINGTON, New Zealand, July 23, 2019 /PRNewswire/ -- Volpara Solutions and ScreenPoint Medical BV today announced signature of an agreement under which Volpara will sell ScreenPoint's Transpara™ products to breast imaging clinics in the United States, Australia, New Zealand, and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the US Food & Drug Administration (FDA).

FDA clearance was supported by the results of a multi-reader, multi-case reader study published in February 2019 by Rodríguez-Ruiz, et. al, in Radiology, which demonstrated that radiologists using Transpara significantly improved detection accuracy without increasing reading times. Radiologists' performance consistently improved independent of their level of experience. In the groundbreaking JNCI publication that followed in March, it was reported that when compared to 101 radiologists, the stand-alone performance (sensitivity and specificity) of Transpara was as accurate. This suggests that the system gives an objective second opinion similar to that of a second radiologist.

Transpara gained European regulatory approval (CE) for use with multi-vendor mammography (2018) and digital breast tomosynthesis (DBT) images (2019) and is already installed at leading breast imaging centers in Europe.
stats
DOTmed text ad

Reveal Mobi Pro now available for sale in the US

Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.

stats
Mark Koeniguer, Volpara Chief Commercial Officer, said: "We see Transpara as a perfect complement to our industry-leading Volpara®Enterprise™ and Volpara®Live!™ image-quality-management products. More can be seen in images by Transpara when images are of good quality."

"Based on the published research to date, we strongly believe that Transpara will deliver both improved mammographic cancer detection and enhanced workflow," said Dr. Ralph Highnam, Volpara CEO. "We are delighted to have ScreenPoint join our common cause and bring this powerful software to our customers."

Prof. Nico Karssemeijer, PhD, ScreenPoint Medical CEO, said: "I am excited that ScreenPoint and Volpara will now partner to bring Transpara to the United States and other markets, as Volpara is well established in the breast space globally. Together, the two companies will help breast care teams detect cancer earlier, streamline mammography reading, and personalize screening for women."

You Must Be Logged In To Post A Comment